水仙直播 announced today success in securing funds, totalling over 拢8m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (), the UK Department of Health and Social Care Small Business Research Initiative () and equity investment led by聽.
These funds will be used to advance our dual-target aminoacy-tRNA synthetase inhibitor (DaaRSi) project, which is developing new antibiotics effective against drug-resistant 鈥楽uperbugs鈥� and to continue development of our proprietry machine learning platform to tackle other valuable pharmaceutical targets.
, the world鈥檚 largest public-private partnership focused on funding the advancement of Gram-negative antibiotics, has agreed to back the DaaRSi project with a milestone dependent, non-dilutive, award for over 拢5m. This will be further accelerated by an award of 拢2M from the DHSC聽聽funding stream and equity investment led by聽, which launched Britain鈥檚 first therapeutics and AI fund earlier this year.